<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204475">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427258</url>
  </required_header>
  <id_info>
    <org_study_id>3200A3-1106</org_study_id>
    <nct_id>NCT00427258</nct_id>
  </id_info>
  <brief_title>Study Evaluating MOA-728 Administered in Healthy Men</brief_title>
  <official_title>An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]MOA-728 in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <brief_summary>
    <textblock>
      Absorption, distribution, metabolism, and excretion (ADME) study with 14C in healthy young
      men.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2010</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of drug using radioactive study drug.</measure>
  </primary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOA-728</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 18 to 50 years inclusive at screening.

          -  Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight â‰¥50 kg. BMI
             is calculated by taking the subject's weight, in kilograms, divided by the square of
             the subject's height, in meters, at screening: BMI = weight (kg)/[height (m)]2

          -  Healthy as determined by the investigator on the basis of screening evaluations.

          -  Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history.
             Must be able to abstain from smoking during the inpatient stay.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Cohn</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals International, Inc.</affiliation>
  </overall_official>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 22, 2011</lastchanged_date>
  <firstreceived_date>January 25, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Jeff Cohn</name_title>
    <organization>Salix Pharmaceuticals</organization>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
